Literature DB >> 11519732

Mechanism of myelin breakdown in experimental demyelination: a putative role for calpain.

K E Schaecher1, D C Shields, N L Banik.   

Abstract

Although calpain has been extensively studied, its physiological function is poorly understood. In contrast, its role in the pathophysiology of various diseases has been implicated, including that of experimental allergic encephalomyelitis (EAE), an animal model of the demyelinating disease multiple sclerosis (MS). In EAE, calpain degrades myelin proteins, including myelin basic protein (MBP), suggesting a role for calpain in the breakdown of myelin in this disease. Subsequent studies revealed increased calpain activity and expression in the glial and inflammatory cells concomitant with loss of axon and myelin proteins. This suggested a crucial role for calpain in demyelinating diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11519732     DOI: 10.1023/a:1010903823668

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  45 in total

1.  Degradation of exogenous MBP by myelin Ca(2+)-activated neutral protease and effect of extraction of myelin on enzyme activity.

Authors:  E Kolehmainen; T Kaisto
Journal:  Neurochem Int       Date:  1989       Impact factor: 3.921

Review 2.  Proteolysis and myelin breakdown: a review of recent histochemical and biochemical studies.

Authors:  J F Hallpike; C W Adams
Journal:  Histochem J       Date:  1969-11

3.  Specific cleavage of the A1 protein from myelin with cathepsin D.

Authors:  S W Brostoff; W Reuter; M Hichens; E H Eylar
Journal:  J Biol Chem       Date:  1974-01-25       Impact factor: 5.157

4.  Calcium-stimulated proteolysis in myelin: evidence for a Ca2+-activated neutral proteinase associated with purified myelin of rat CNS.

Authors:  N L Banik; W W McAlhaney; E L Hogan
Journal:  J Neurochem       Date:  1985-08       Impact factor: 5.372

5.  Antigen processing of myelin basic protein is required prior to recognition by T cells inducing EAE.

Authors:  A H Cross; S Dolich; C S Raine
Journal:  Cell Immunol       Date:  1990-08       Impact factor: 4.868

6.  Oligodendrocyte susceptibility to injury by T-cell perforin.

Authors:  N J Scolding; J Jones; D A Compston; B P Morgan
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

7.  Positive regulation of mu-calpain action by polyphosphoinositides.

Authors:  T C Saido; M Shibata; T Takenawa; H Murofushi; K Suzuki
Journal:  J Biol Chem       Date:  1992-12-05       Impact factor: 5.157

8.  Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease.

Authors:  N Iwamoto; W Thangnipon; C Crawford; P C Emson
Journal:  Brain Res       Date:  1991-10-04       Impact factor: 3.252

9.  In vivo CNS demyelination mediated by anti-galactocerebroside antibody.

Authors:  K Ozawa; T Saida; K Saida; H Nishitani; M Kameyama
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

10.  Intracellular Ca2+ stores of T lymphocytes: changes induced by in vitro and in vivo activation.

Authors:  E Clementi; G Martino; L M Grimaldi; E Brambilla; J Meldolesi
Journal:  Eur J Immunol       Date:  1994-06       Impact factor: 5.532

View more
  19 in total

1.  Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients.

Authors:  Amena W Smith; Bently P Doonan; William R Tyor; Nada Abou-Fayssal; Azizul Haque; Naren L Banik
Journal:  J Neuroimmunol       Date:  2010-11-13       Impact factor: 3.478

2.  Sustained calpain inhibition improves locomotor function and tissue sparing following contusive spinal cord injury.

Authors:  Chen-Guang Yu; James W Geddes
Journal:  Neurochem Res       Date:  2007-05-03       Impact factor: 3.996

3.  Site-specific degradation of myelin basic protein by the proteasome.

Authors:  A A Belogurov; N A Ponomarenko; V M Govorun; A G Gabibov; A V Bacheva
Journal:  Dokl Biochem Biophys       Date:  2009 Mar-Apr       Impact factor: 0.788

4.  Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury.

Authors:  Chen-Guang Yu; Aashish Joshi; James W Geddes
Journal:  J Neurotrauma       Date:  2008-07       Impact factor: 5.269

5.  Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis.

Authors:  M Kelly Guyton; Arabinda Das; Supriti Samantaray; Gerald C Wallace; Jonathan T Butler; Swapan K Ray; Naren L Banik
Journal:  J Neurosci Res       Date:  2010-08-15       Impact factor: 4.164

6.  Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis.

Authors:  Nicole Trager; Amena Smith; Gerald Wallace Iv; Mitsuyoshi Azuma; Jun Inoue; Craig Beeson; Azizul Haque; Naren L Banik
Journal:  J Neurochem       Date:  2014-02-12       Impact factor: 5.372

Review 7.  Neuroprotection in multiple sclerosis: a therapeutic approach.

Authors:  Amir-Hadi Maghzi; Alireza Minagar; Emmanuelle Waubant
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

8.  Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells.

Authors:  Mary K Guyton; Saurav Brahmachari; Arabinda Das; Supriti Samantaray; Jun Inoue; Mitsuyoshi Azuma; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2009-07-17       Impact factor: 5.372

9.  Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry.

Authors:  Andrew K Ottens; Erin C Golden; Liliana Bustamante; Ronald L Hayes; Nancy D Denslow; Kevin K W Wang
Journal:  J Neurochem       Date:  2007-11-22       Impact factor: 5.372

10.  Glutamate excitotoxicity inflicts paranodal myelin splitting and retraction.

Authors:  Yan Fu; Wenjing Sun; Yunzhou Shi; Riyi Shi; Ji-Xin Cheng
Journal:  PLoS One       Date:  2009-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.